164 related articles for article (PubMed ID: 12650430)
1. Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Sampath P; Amundson E; Wall ME; Tyler BM; Wani MC; Alderson LM; Colvin M; Brem H; Weingart JD
J Neurosurg; 2003 Mar; 98(3):570-7. PubMed ID: 12650430
[TBL] [Abstract][Full Text] [Related]
2. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Storm PB; Renard VM; Moriarity JL; Tyler B; Wilentz RE; Brem H; Weingart JD
Cancer Chemother Pharmacol; 2004 Oct; 54(4):361-7. PubMed ID: 15197484
[TBL] [Abstract][Full Text] [Related]
3. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
Adams DJ; Wahl ML; Flowers JL; Sen B; Colvin M; Dewhirst MW; Manikumar G; Wani MC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):145-54. PubMed ID: 16001167
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
[TBL] [Abstract][Full Text] [Related]
6. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Coggins CA; Elion GB; Houghton PJ; Hare CB; Keir S; Colvin OM; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1998; 41(6):485-90. PubMed ID: 9554593
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Friedman HS; Keir ST; Houghton PJ
Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457
[TBL] [Abstract][Full Text] [Related]
10. [Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
Noshuyo Byori; 1994; 11(1):59-64. PubMed ID: 8162152
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
12. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
13. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Valenti M; Nieves-Neira W; Kohlhagen G; Kohn KW; Wall ME; Wani MC; Pommier Y
Mol Pharmacol; 1997 Jul; 52(1):82-7. PubMed ID: 9224816
[TBL] [Abstract][Full Text] [Related]
14. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
[TBL] [Abstract][Full Text] [Related]
15. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R
Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512
[TBL] [Abstract][Full Text] [Related]
17. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Wadkins RM; Bearss D; Manikumar G; Wani MC; Wall ME; Von Hoff DD
Cancer Res; 2004 Sep; 64(18):6679-83. PubMed ID: 15374984
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.
Adams DJ; da Silva MW; Flowers JL; Kohlhagen G; Pommier Y; Colvin OM; Manikumar G; Wani MC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):135-44. PubMed ID: 16151810
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Chen TC; Su S; Fry D; Liebes L
Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
